Gout Cavalcade (7.10.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.
Read Article
EULAR26: Reports on Systemic Sclerosis
https://t.co/knZZlMYlen https://t.co/0wul0yaw4m
Dr. John Cush @RheumNow( View Tweet )
EULAR26: Reports on Systemic Sclerosis
EurekAlert!
In an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity index (
Read Article
From BiTE to TriTE: Progress of T-cell Engagers in RMDs
The EULAR 2026 Congress in London showcased growing interest in T-cell engagers as a novel strategy to achieve deep B-cell depletion and drug-free remission in refractory rheumatic and musculoskeletal diseases (RMDs). Bispecific T-cell engagers (BiTE) aim to overcome limitations of
Read Article
NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.
Read Article
Day 2 Report from EULAR 2026
Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease. Here are a few of my favorites from Day 2
https://t.co/6KwtkMNLAf https://t.co/Toh4HNZFN5
Dr. John Cush @RheumNow( View Tweet )
Abstr LB0003
Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered.
RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD.
Curious about long term results and potential position in tx strategies
LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO
Links:
sheila @RHEUMarampa( View Tweet )
CAR-T without the CAR-T risks?
AB-101, an off-the-shelf NK cell therapy + RTX, delivered in refractory RA, Sjögren, and SSc (n=31): RA ACR50 71%, SSc mRSS -9.5, SjD ClinESS DAI -8.6 at 6 mo. Outpatient delivery without CAR-T associated AEs? @RheumNow #EULAR2026 LB0003 https://t.co/xi6ZdLwHcN
Jiha Lee @JihaRheum( View Tweet )
Improving Understanding in SSc
2026 EULAR Press Release
Systemic sclerosis is a rare connective tissue disorder characterised by autoimmune features with vascular manifestations, causing fibrosis of the skin and internal organs. EULAR is focused on systemic sclerosis as the rheumatic disease with the highest morbidity and mortality. New data
Read Article
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read Article
#CAR_T cell therapy in #SSc
Promising results from the Breakfree-1 study
(Zola-cel) on safety and preliminary efficacy on pFVC in 26 patients
More data is needed
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/ZS1LnBLMu5
Links:
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Looking forward to CAR T cell therapy trials in #SSc
Phase 2 and 3 studies presented at
#HOT session by Pr Oliver Distler
#CAR_T
#EULAR2026 @RheumNow https://t.co/bmXZpF2wKg
Links:
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Many drugs in the pipeline for #Systemic_Sclerosis
In particular, stay tuned for:
🔺Nerandomilast (PDE4i) in ILD
🔺CAR T cells (obviously): big RCT trials planned
🔺Bispecific T cell engagers: Teclistamab
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/I7HQtfwuW0
Links:
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Digital Platforms and AI
2026 EULAR Press Release
EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that
Read Article
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
❎HIGH Type 1 #interferon
=
Worse #scleroderma
In both
#limited #lcSSc
&
#diffuse #dcSSc
Leeds cohort
?biomarker
#EULAR2026 @RheumNow ABST#POS1092
ABST#POS0395 https://t.co/cRrBIpLgP9
Links:
Janet Pope @Janetbirdope( View Tweet )
#EULAR2026 OP077 Another promising CAR-T in autoimmunity. In a Phase II study, Rap-Cel autologous CD19 CAR-T (shorter infusion time ~2d & low dose) vs traditional CAR-T showed drug-free improvement in N=6 #IIM & N=6 #SSc patients. Safety similar to other CAR-Ts @RheumNow https://t.co/byNn5X8JGh
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2026 OP076 Of 50 patients treated with autologous CAR-T, 12% relapsed; median 13 mths. More frequent in #IIM vs #SLE or #SSc. These relapses were significant. Switching to BCMA-CAR or BCMA-TCE restored response. Should BCMA instead of CD19 be targeted initially?@RheumNow https://t.co/lgdsJQm3xY
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
CAR-T Cell Therapies in Refractory RMD
EULAR 2026 Press Release
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed chimeric antigen receptor T (CAR-T) cell therapy may be an
Read Article
Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/k7tVeJFeCi
Dr. John Cush @RheumNow( View Tweet )
Adverse drug events (ADEs) studied in autoimmune rheum Dz (ARDs). In 10,578 ARD pts 30% had 1+ ADE, highest in SSc (36%). Polypharmacy (57.3% minor, 39.4% major) contrib to increasing ADEs. ADEs were more from Sx Rx (antacids, Tylenol, psychotropics) than DMARDs. https://t.co/BOAfU1DyIN
Dr. John Cush @RheumNow( View Tweet )
Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/jtHgVABFiA
Dr. John Cush @RheumNow( View Tweet )
Early GI Involvement Predictive of Scleroderma Outcomes
Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).
Infectious Rheumatology (5.15.2026)
Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.
Read ArticleRecent Blogs
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
How best do we communicate CV risk associated with RA to other members of the treating team, most particularly the primary care physicians? After some experimentation, I have come up with an approach that seems to work and which does not take up much time.
Read Post
Podcasts
EULAR 2026 Daily Podcast Day 2c
EULAR 2021 - Day2a00:38:00
